<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220718055488N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-28</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Methyl Prednisolone Acetate injection at the Jianqian Acupoint   in Patients with Non Specific Shoulder Pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effectiveness of Methyl Prednisolone Acetate Injection at the Jianqian Acupoint versus Oral Piroxicam in Reducing Pain and Improving Function in patients with Non Specific Shoulder Pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>58</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64847</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random allocation method in this study will be permutation block method in such a way that A represents the person for whom injection is done and B represents the person who receives oral Piroxicam. This method is based on blocks of six so that the total number of possible permutations of six is ​​equal to 6 (including: ABAB, BABA, AABB, BBAA, ABBA and BAAB). Then, by using   the table of random numbers and assigning a code from 0 to 9 to each of the permutations, the desired random list of 60 items, which includes 15 blocks of 4 items (total number of samples = 60 x 15) is generated and the order of assigning each One of the methods is specified for each of the samples participating in the study, Blinding description: Participant: In this study, we do not have the ability to blind the patient because the patients are aware of the type of intervention.
Clinical caregiver: We train the person who is in charge of the care and follow-up of patients how to complete the questionnaire. This person has no awareness of the patient's intervention.
Researcher: In this study, we do not have the ability to blind the researcher because the intervention is carried out by him. 
Outcome assessor: Completed questionnaires are given to a person who  does not know about the interventions and he is asked to determine the amount of pain reduction and performance improvement in each person according to the questionnaire.
Data Analyzer:Finally, after completing and collecting all the information, the questionnaires are given to a person to check the information, who does not know about any of the work steps and how the intervention is divided.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Non Specific Shoulder Pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: At the Jianqian acupoint, which is between the axillary fold and the LI-15 acupoint (under the acromion), we inject a mixture of 40 mg of Methyl Prednisolone Acetate and 4 ml of  Lidocaine2% in 5 directions in such a way that First, we insert the needle perpendicularly about 1.5 to 2 cm on the joint surface and outside the capsule and inject 1 cc of the substance, then without removing the needle, by changing the direction angle to 40 degrees to the vertical line , at upward ,downward and outside , we inject one cc on each side. At the inside, we enter at an angle of 10 degrees to the perpendicular line close to the joint capsule, and we are careful not to enter the pleura, and the injection is done. During the injection, we pay attention to the patient's reactions so as not to enter the blood vessels and nerves. Intervention 2: Control group: They take 10 mg Piroxicam capsules twice daily after meal and with enough water.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after making people unidentifiable.

When:
Start access period one year after publishing the results.

To whom:
Everyone can access to this information.

Conditions:
If the information in this study helps to improve the science process.

Where to obtain:
dr.lale zare
dr.lalezare@gmail.com

How to obtain:
After sending the desired message, all authors of the study will be consulted, all information will be sent within a maximum of three weeks if permitted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Lale Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.3, 2nd Alley, Rayehe Ave, Golestan Town</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7189895361</zip>
        <telephone>+98 71 3621 2959</telephone>
        <email>dr.lalezare@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Lale Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 3, 2nd Alley, Rayehe Ave, Golestan Town</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7189895361</zip>
        <telephone>+98 71 3621 2959</telephone>
        <email>dr.lalezare@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years old
Non-specific shoulder pain lasted more than 6 weeks
Limitation of active range of motion in at least one plane
Absence of any disease around the affected shoulder
Completing and signing the informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any systemic or local infection
Acute trauma
Fracture or Dislocation
Malignancy
Liver or Renal failure
Gastrointestinal disease, Cardiovascular disease, Asthma, DM, uncontrolled HTN
History of injection or physical therapy during the last month
Clinical symptoms of inflammation or infection
Severe deformity of shoulder
Any bleeding tendency disorders or use of anti coagulants
Active rheumatologic disease
Post stroke shoulder pain
History of allergic reactions to the used drugs
Pregnant or Lactating women
Inability to communicate and completing questionnaires</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M25.519</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain in unspecified shoulder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: At the Jianqian acupoint, which is between the axillary fold and the LI-15 acupoint (under the acromion), we inject a mixture of 40 mg of Methyl Prednisolone Acetate and 4 ml of  Lidocaine2% in 5 directions in such a way that First, we insert the needle perpendicularly about 1.5 to 2 cm on the joint surface and outside the capsule and inject 1 cc of the substance, then without removing the needle, by changing the direction angle to 40 degrees to the vertical line , at upward ,downward and outside , we inject one cc on each side. At the inside, we enter at an angle of 10 degrees to the perpendicular line close to the joint capsule, and we are careful not to enter the pleura, and the injection is done. During the injection, we pay attention to the patient's reactions so as not to enter the blood vessels and nerves.</i_keyword>
      <i_keyword>Control group: They take 10 mg Piroxicam capsules twice daily after meal and with enough water.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shoulder pain. Timepoint: Before intervention and two, four and eight weeks after intervention. Method of measurement: Visual Analog Scale and Oxford Shoulder Score questionnaires.</prim_outcome>
      <prim_outcome>Range of motion of shoulder. Timepoint: Before intervention and two, four and eight weeks after intervention. Method of measurement: By goniometer, which is a device for measuring angles, the one that is used in this study is a plastic type with 360 degree rotation and an arm  length of 30 cm.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Function of patient. Timepoint: Before intervention and two, four and eight weeks after intervention. Method of measurement: Shoulder Pain And Disability Index and Oxford Shoulder Scale questionnaires.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-23</approval_date>
        <contact_name>Ethics committee ofShiraz University of Medical Sciences</contact_name>
        <contact_address>Shiraz university of medical science, Zand Ave Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
